Skip to main content
SpringerLink
Log in

Melanoma and Quality of Life

  • Chapter
  • First Online:
Handbook of Quality of Life in Cancer

Abstract

Melanoma is a skin cancer affecting mostly people of fair skinned ancestry. Treatment of melanoma at each stage of disease is very different, and therefore results in distinct physical and subsequently psychological and quality of life (QoL) issues. Surgery is the main treatment for primary melanoma and nodal metastases. The advent of new drug therapy (immune therapy and targeted therapy) for more advanced disease has significantly improved survival outcomes, albeit with side effects of treatment and therefore changed the QoL issues experienced by survivors of disease. This chapter aims to summarise these issues.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Institute for Cancer Research. World Cancer Research Fund – Continuous Update Project: American Institute for Cancer Research; 2020. Available from: https://www.wcrf.org/dietandcancer/cancer-trends/skin-cancer-statistics.

  2. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92.

    Article  Google Scholar 

  3. Cancer Council Australia. Australian clinical practice guidelines for the diagnosis and management of melanoma: Cancer Council Australia; 2019. Available from: https://wiki.cancer.org.au/australia/Guidelines:Melanoma.

  4. Annunziata MA, Muzzatti B, Flaiban C, Gipponi K, Carnaghi C, Tralongo P, et al. Long-term quality of life profile in oncology: a comparison between cancer survivors and the general population. Support Care Cancer. 2018;26(2):651–6.

    Article  Google Scholar 

  5. Paltrinieri S, Fugazzaro S, Bertozzi L, Bassi M, Pellegrini M, Vicentini M, et al. Return to work in European cancer survivors: a systematic review. Support Care Cancer. 2018;26(9):2983–94.

    Article  Google Scholar 

  6. Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10(1):19–28.

    Article  Google Scholar 

  7. Boekhout AH, Rogiers A, Jozwiak K, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, et al. Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. Acta Oncol. 2020;60(1):69–77, https://doi.org/10.1080/0284186X.2020.1818823.

  8. Barcaccia B, Esposito G, Matarese M, Bertolaso M, Elvira M, De Marinis M. Defining quality of life: a wild-goose chase? Eur J Psychol. 2013;9(1):185–203.

    Article  Google Scholar 

  9. Cormier JN, Cromwell KD, Ross MI. Health-related quality of life in patients with melanoma: overview of instruments and outcomes. Dermatol Clin. 2012;30(2):245–54, viii.

    Article  Google Scholar 

  10. Burdon-Jones D, Gibbons K. The Skin Cancer Quality of Life Impact Tool (SCQOLIT): a validated health-related quality of life questionnaire for non-metastatic skin cancers. J Eur Acad Dermatol Venereol. 2013;27(9):1109–13.

    Article  Google Scholar 

  11. Sigurdardottir V, Bolund C, Brandberg Y, Sullivan M. The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res. 1993;2(3):193–203.

    Article  Google Scholar 

  12. Cella D. Quality of life outcomes: measurement and intervention. J Support Oncol. 2005;3(2):133–4.

    Google Scholar 

  13. Winstanley JB, Saw R, Boyle F, Thompson J. The FACT-melanoma quality-of-life instrument: comparison of a five-point and four-point response scale using the Rasch measurement model. Melanoma Res. 2013;23(1):61–9.

    Article  Google Scholar 

  14. Winstanley JB, Young TE, Boyle FM, Bergenmar M, Bottomley A, Burmeister B, et al. Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module. Melanoma Res. 2015;25(1):47–58.

    Article  Google Scholar 

  15. Winstanley J, White E, Saw R, Young T, Burmeister B, Nikolic D, et al. Development of the Melanoma Concerns Questionnaire (MCQ-28); refinement of the EORTC QLQ-MEL38 module. Psychooncology. 2020;29(2):321–30.

    Article  Google Scholar 

  16. Health Do. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0) Commonwealth of Australia; 2016.

    Google Scholar 

  17. Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.

    Google Scholar 

  18. Neumann PJ, Willke RJ, Garrison LP Jr. Health economics approach to US value assessment frameworks-introduction: an ISPOR Special Task Force report value health. Value Health. 2018;21(2):119–23.

    Article  Google Scholar 

  19. Clemens S, Begum N, Harper C, Whitty JA, Scuffham PA. A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA. Qual Life Res. 2014;23(8):2375–81.

    Article  Google Scholar 

  20. Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202–10.

    Article  Google Scholar 

  21. Morton RL. Essential inputs for studies of cost-effectiveness analysis in melanoma. Br J Dermatol. 2014;171(6):1294–5.

    Article  Google Scholar 

  22. Morton RL, Tran A, Vessey JY, Rowbotham N, Winstanley J, Shannon K, et al. Quality of life following sentinel node biopsy for primary cutaneous melanoma: health economic implications. Ann Surg Oncol. 2017;24(8):2071–9.

    Article  Google Scholar 

  23. Dieng M, Kasparian NA, Cust AE, Costa DSJ, Tran A, Butow PN, et al. Sensitivity of preference-based quality-of-life measures for economic evaluations in early-stage melanoma. JAMA Dermatol. 2018;154(1):52–9.

    Article  Google Scholar 

  24. Macbeth F, Newton-Bishop J, O’Connell S, Hawkins JE, Guideline Development Group. Melanoma: summary of NICE guidance. BMJ. 2015;351:h3708.

    Google Scholar 

  25. Oliveria SA, Hay JL, Geller AC, Heneghan MK, McCabe MS, Halpern AC. Melanoma survivorship: research opportunities. J Cancer Surviv Res Pract. 2007;1(1):87–97.

    Article  Google Scholar 

  26. Lisy K, Lai-Kwon J, Ward A, Sandhu S, Kasparian NA, Winstanley J, et al. Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study. Qual Life Res. 2020;29:2021–2027.

    Google Scholar 

  27. Cornish D, Holterhues C, Van de Poll-Franse L, Coebergh JW, Nijsten T. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol. 2009;20(suppl_6):vi51–8.

    Google Scholar 

  28. Pereira MG, Ponte M, Ferreira G, Machado JC. Quality of life in patients with skin tumors: the mediator role of body image and social support. Psychooncology. 2017;26(6):815–21.

    Article  Google Scholar 

  29. Bassino S, Ribero S, Miniotti M, Picardi A, Caliendo V, Castelli L, et al. Emotional distress and health-related quality of life among cutaneous melanoma follow-up outpatients: the role of self-perception of body image and surgical scarring. Eur J Dermatol. 2017;27(4):435–8.

    Article  Google Scholar 

  30. Stamataki Z, Brunton L, Lorigan P, Green AC, Newton-Bishop J, Molassiotis A. Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma. Support Care Cancer. 2015;23(3):779–89.

    Article  Google Scholar 

  31. Vogel RI, Strayer LG, Ahmed RL, Blaes A, Lazovich D. A qualitative study of quality of life concerns following a melanoma diagnosis. J Skin Cancer. 2017;2017:2041872.

    Google Scholar 

  32. Atkinson TM, Noce NS, Hay J, Rafferty BT, Brady MS. Illness-related distress in women with clinically localized cutaneous melanoma. Ann Surg Oncol. 2013;20(2):675–9.

    Article  Google Scholar 

  33. Newton-Bishop JA, Nolan C, Turner F, McCabe M, Barrett JH, Boxer C, et al. A quality-of-life study in high-risk (thickness ≥2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc. 2004;9(2):152–9.

    Article  Google Scholar 

  34. Mori S, Blank NR, Connolly KL, Dusza SW, Nehal KS, Rossi AM, et al. Association of quality of life with surgical excision of early-stage melanoma of the head and neck. JAMA Dermatol. 2019;155(1):85–9.

    Article  Google Scholar 

  35. Banting S, Gyorki DE. ASO author reflections: the impacts of a negative sentinel lymph node on quality of life. Ann Surg Oncol. 2019;26(3):651–2.

    Article  Google Scholar 

  36. Moody J, Ali R, Carbone A, Singh S, Hardwicke J. Complications of sentinel lymph node biopsy for melanoma–a systematic review of the literature. Eur J Surg Oncol (EJSO). 2017;43(2):270–7.

    Article  Google Scholar 

  37. Banting S, Milne D, Thorpe T, Na L, Spillane J, Speakman D, et al. Negative sentinel lymph node biopsy in patients with melanoma: the patient’s perspective. Ann Surg Oncol. 2019;26(7):2263–7.

    Article  Google Scholar 

  38. Tesio V, Ribero S, Castelli L, Bassino S, Leombruni P, Caliendo V, et al. Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients. Melanoma Res. 2017;27(3):277–80.

    Article  Google Scholar 

  39. Heino PJ, Mylläri PH, Jahkola TA, Sintonen H, Luoma M-L, Räsänen P, et al. Long-term quality of life of melanoma survivors is comparable to that of the general population. Anticancer Res. 2019;39(5):2633–40.

    Article  Google Scholar 

  40. Holterhues C, Cornish D, van de Poll-Franse LV, Krekels G, Koedijk F, Kuijpers D, et al. Impact of melanoma on patients’ lives among 562 survivors: a Dutch population-based study. Arch Dermatol. 2011;147(2):177–85.

    Article  Google Scholar 

  41. Vogel RI, Strayer LG, Engelman L, Nelson HH, Blaes AH, Anderson KE, et al. Comparison of quality of life among long-term melanoma survivors and non-melanoma controls: a cross-sectional study. Qual Life Res. 2017;26(7):1761–6.

    Article  Google Scholar 

  42. de Vries M, Hoekstra HJ, Hoekstra-Weebers JE. Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16(10):2840–7.

    Article  Google Scholar 

  43. Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999;48(11):1507–15.

    Article  Google Scholar 

  44. Gjorup CA, Groenvold M, Hendel HW, Dahlstroem K, Drzewiecki KT, Klausen TW, et al. Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema. Eur J Cancer. 2017;85:122–32.

    Google Scholar 

  45. Oliveria SA, Shuk E, Hay JL, Heneghan M, Goulart JM, Panageas K, et al. Melanoma survivors: health behaviors, surveillance, psychosocial factors, and family concerns. Psycho-Oncology. 2013;22(1):106–16.

    Article  Google Scholar 

  46. Morton RL, Tran A, Vessey JY, Rowbotham N, Winstanley J, Shannon K, et al. Quality of life following sentinel node biopsy surgery for primary cutaneous melanoma: implications for health economics. Ann Surg Oncol. 2016;24(8):2071–9.

    Article  Google Scholar 

  47. Beesley VL, Smithers BM, Khosrotehrani K, Khatun M, O’Rourke P, Hughes MC, et al. Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia. Psychooncology. 2015;24(7):763–70.

    Article  Google Scholar 

  48. Miniotti M, Zeneli A, Bassino S, Pavan S, Ribero S, Leombruni P. Prevalence and correlates of the supportive care needs of Italian early-stage melanoma patients in follow-up. J Psychosoc Oncol. 2019;37(6):746–57.

    Article  Google Scholar 

  49. Fu H, Teleni L, Crichton M, Chan RJ. Supportive care and unmet needs in patients with melanoma: a mixed-methods systematic review. Support Care Cancer. 2020;28:3489–501.

    Article  Google Scholar 

  50. Williamson TJ, Jorge-Miller A, McCannel TA, Beran TM, Stanton AL. Sociodemographic, medical, and psychosocial factors associated with supportive care needs in adults diagnosed with uveal melanoma. JAMA Ophthalmol. 2018;136(4):356–63.

    Article  Google Scholar 

  51. Engel J, Schlesinger-Raab A, Emeny R, Hölzel D, Schubert-Fritschle G. Quality of life in women with localised breast cancer or malignant melanoma 2 years after initial treatment: a comparison. Int J Behav Med. 2014;21(3):478–86.

    Article  Google Scholar 

  52. Dieng M, Butow PN, Costa D, Morton RL, Menzies SW, Mireskandari S, et al. Psychoeducational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: results of a randomized controlled trial. J Clin Oncol. 2016;34(36):4405–14.

    Article  Google Scholar 

  53. Dieng M, Morton R, Costa D, Butow P, Menzies S, Lo S, et al. Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomized controlled trial. Br J Dermatol. 2019;182(4):860–8.

    Article  Google Scholar 

  54. Rychetnik L, McCaffery K, Morton R, Irwig L. Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. Psycho-Oncology. 2013;22(4):721–36.

    Article  Google Scholar 

  55. Molassiotis A, Brunton L, Hodgetts J, Green A, Beesley V, Mulatero C, et al. Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. Ann Oncol. 2014;25(10):2052–8.

    Article  Google Scholar 

  56. Toscano A, Blanchin M, Bourdon M, Antignac AB, Sébille V. Longitudinal associations between coping strategies, locus of control and health-related quality of life in patients with breast cancer or melanoma. Qual Life Res. 2020;29:1271–1279.

    Google Scholar 

  57. Bastiaannet E, Hoekstra-Weebers JE, Francken AB, Jager PL, van der Jagt EJ, Hoekstra HJ. Perception of burden experienced during diagnostic tests by melanoma patients with lymph node metastases. Melanoma Res. 2009;19(1):36–41.

    Google Scholar 

  58. Egger ME, Kimbrough CW, Stromberg AJ, Quillo AR, Martin RCG, Scoggins CR, et al. Melanoma patient-reported quality of life outcomes following sentinel lymph node biopsy, completion lymphadenectomy, and adjuvant interferon: results from the sunbelt melanoma trial. Ann Surg Oncol. 2016;23(3):1019–25.

    Article  Google Scholar 

  59. Dunn J, Watson M, Aitken JF, Hyde MK. Systematic review of psychosocial outcomes for patients with advanced melanoma. Psycho-Oncology. 2017;26(11):1722–31.

    Article  Google Scholar 

  60. Tan JD, Butow PN, Boyle FM, Saw RPM, O’Reilly AJ. A qualitative assessment of psychosocial impact, coping and adjustment in high-risk melanoma patients and caregivers. Melanoma Res. 2014;24(3):252–60.

    Google Scholar 

  61. Cromwell KD, Chiang YJ, Armer J, Heppner PP, Mungovan K, Ross MI, et al. Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. Eur J Cancer Care (Engl). 2015;24(5):724–33.

    Article  Google Scholar 

  62. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22.

    Article  Google Scholar 

  63. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37(32):3000–8.

    Article  Google Scholar 

  64. Blank CU, Reijers ILM, Pennington T, Versluis JM, Saw RPM, Rozeman EA, et al. First safety and efficacy results of PRADO: a phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol. 2020;38(15_suppl):10002.

    Google Scholar 

  65. Bagge A-SL, Ben-Shabat I, Belgrano V, Olofsson Bagge R. Health-related quality of life for patients who have in-transit melanoma metastases treated with isolated limb perfusion. Ann Surg Oncol. 2016;23(6):2062–9.

    Article  Google Scholar 

  66. Jiang BS, Speicher PJ, Thomas S, Mosca PJ, Abernethy AP, Tyler DS. Quality of life after isolated limb infusion for in-transit melanoma of the extremity. Ann Surg Oncol. 2015;22(5):1694–700.

    Article  Google Scholar 

  67. Coens C, Suciu S, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017;18(3):393–403.

    Article  Google Scholar 

  68. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.

    Article  Google Scholar 

  69. Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson V, Dalle S, et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up. J Clin Oncol. 2020;38(15_suppl):10000.

    Google Scholar 

  70. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801.

    Article  Google Scholar 

  71. Schadendorf D, Di Giacomo AM, Demidov L, Merelli B, Bondarenko I, Ascierto PA, et al. Health-related quality of life in patients with fully resected BRAF V600 mutation positive melanoma receiving adjuvant vemurafenib. Eur J Cancer. 2019;123:155–61.

    Google Scholar 

  72. Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(5):701–10.

    Article  Google Scholar 

  73. Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, et al. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016;67:46–54.

    Google Scholar 

  74. Petrella TM, Robert C, Richtig E, Miller WH, Masucci GV, Walpole E, et al. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. Eur J Cancer. 2017;86:115–24.

    Google Scholar 

  75. Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, et al. Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment naive advanced melanoma (MEL): results of a phase III study (CheckMate 066). Ann Oncol. 2015;26:vi28.

    Google Scholar 

  76. Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017;82:80–91.

    Google Scholar 

  77. Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, et al. Quality-of-life assessment in French patients with metastatic melanoma in real life. Cancer. 2020;126(3):611–8.

    Article  Google Scholar 

  78. Joseph RW, Liu FX, Shillington AC, Macahilig CP, Diede SJ, Dave V, et al. Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. Qual Life Res. 2020;29(10):2651–60.

    Article  Google Scholar 

  79. Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, et al. Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma. Br J Cancer. 2018;118(6):777–84.

    Article  Google Scholar 

  80. Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389–98.

    Article  Google Scholar 

  81. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015;51(7):833–40.

    Article  Google Scholar 

  82. Tufvesson Stiller H, Mikiver R, Uppugunduri S, Lindholm C, Månsson Brahme E, Schmitt-Egenolf M. Health-related quality of life in patients with melanoma – characterization of a Swedish cohort. Br J Dermatol. 2020;182(2):506–8.

    Article  Google Scholar 

  83. Weitman ES, Perez M, Thompson JF, Andtbacka RHI, Dalton J, Martin ML, et al. Quality of life patient-reported outcomes for locally advanced cutaneous melanoma. Melanoma Res. 2018;28(2):134–42.

    Article  Google Scholar 

  84. Milne D, Hyatt A, Billett A, Gough K, Krishnasamy M. Exploring the experiences of people treated with immunotherapies for advanced melanoma and those caring for them: “real-world” data. Cancer Nurs. 2020;43(2):E97–104.

    Google Scholar 

  85. Lai-Kwon J, Khoo C, Lo S, Milne D, Mohamed M, Raleigh J, et al. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. J Cancer Surviv. 2019;13(4):503–11.

    Article  Google Scholar 

  86. Mamoor M, Postow MA, Lavery JA, Baxi SS, Khan N, Mao JJ, et al. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. J Immunother Cancer. 2020;8(1):e000260.

    Article  Google Scholar 

  87. Patrinely JR, Young AC, Quach H, Williams GR, Ye F, Fan R, et al. Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer. 2020;135:211–20.

    Google Scholar 

  88. Livingstone A, Agarwal A, Stockler MR, Menzies AM, Howard K, Morton RL. Preferences for immunotherapy in melanoma: A systematic review. Ann Surg Oncol. 2020;27(2):571–84.

    Article  Google Scholar 

  89. Rogiers A, Leys C, Lauwyck J, Schembri A, Awada G, Schwarze JK, et al. Neurocognitive function, psychosocial outcome, and health-related quality of life of the first-generation metastatic melanoma survivors treated with ipilimumab. J Immunol Res. 2020;2020:2192480.

    Google Scholar 

  90. Rogiers A, Leys C, De Cremer J, Awada G, Schembri A, Theuns P, et al. Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study. Support Care Cancer. 2020;28(7):3267–78.

    Article  Google Scholar 

  91. Hyatt A, Gough K, Murnane A, Au-Yeung G, Dawson T, Pearson E, et al. i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol. BMJ Open. 2020;10(2):e036059.

    Article  Google Scholar 

  92. Hamama-Raz Y. Does psychological adjustment of melanoma survivors differs between genders? Psycho-Oncology. 2012;21:255–63.

    Article  Google Scholar 

  93. Schlesinger-Raab A, Schubert-Fritschle G, Hein R, Stolz W, Volkenandt M, Hölzel D, et al. Quality of life in localised malignant melanoma. Ann Oncol. 2010;21(12):2428–35.

    Article  Google Scholar 

  94. Hamel J-F, Pe M, Coens C, Martinelli F, Eggermont AM, Brandberg Y, et al. A systematic review examining factors influencing health related quality of life among melanoma cancer survivors. Eur J Cancer. 2016;69:189–98.

    Google Scholar 

  95. Loquai C, Scheurich V, Syring N, Schmidtmann I, Rietz S, Werner A, et al. Screening for distress in routine oncological care—a survey in 520 melanoma patients. PLoS One. 2013;8(7):e66800.

    Article  Google Scholar 

  96. Graugaard C, Sperling CD, Holge-Hazelton B, Boisen KA, Petersen GS. Sexual and romantic challenges among young Danes diagnosed with cancer: results from a cross-sectional nationwide questionnaire study. Psychooncology. 2018;27(6):1608–14.

    Article  Google Scholar 

  97. Skaczkowski G, White V, Thompson K, Bibby H, Coory M, Orme LM, et al. Factors influencing the provision of fertility counseling and impact on quality of life in adolescents and young adults with cancer. J Psychosoc Oncol. 2018;36(4):484–502.

    Article  Google Scholar 

  98. Skaczkowski G, White V, Thompson K, Bibby H, Coory M, Pinkerton R, et al. Do Australian adolescents’ and young adults’ experiences of cancer care influence their quality of life? Psychooncology. 2018;27(3):990–7.

    Article  Google Scholar 

  99. Schubert-Fritschle G, Schlesinger-Raab A, Hein R, Stolz W, Volkenandt M, Hölzel D, et al. Quality of life and comorbidity in localized malignant melanoma: results of a German population-based cohort study. Int J Dermatol. 2013;52(6):693–704.

    Article  Google Scholar 

  100. Kneier AW. Coping with melanoma--ten strategies that promote psychological adjustment. Surg Clin North Am. 2003;83(2):417–30.

    Article  Google Scholar 

  101. Heitzmann CA, Merluzzi TV, Jean-Pierre P, Roscoe JA, Kirsh KL, Passik SD. Assessing self-efficacy for coping with cancer: development and psychometric analysis of the brief version of the Cancer Behavior Inventory (CBI-B). Psychooncology. 2011;20(3):302–12.

    Article  Google Scholar 

  102. Brown JE, Brown RF, Miller RM, Dunn SM, King MT, Coates AS, et al. Coping with metastatic melanoma: the last year of life. Psychooncology. 2000;9(4):283–92.

    Article  Google Scholar 

  103. Kasparian NA, McLoone JK, Butow PN. Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature. Arch Dermatol. 2009;145(12):1415–27.

    Article  Google Scholar 

  104. Beutel ME, Blettner M, Fischbeck S, Loquay C, Werner A, Marian H. Psycho-oncological aspects of malignant melanoma. A systematic review from 1990-2008. Hautarzt. 2009;60(9):727–33.

    Article  Google Scholar 

  105. Wagner T, Augustin M, Blome C, Forschner A, Garbe C, Gutzmer R, et al. Fear of cancer progression in patients with stage IA malignant melanoma. Eur J Cancer Care (Engl). 2018;27(5):e12901.

    Article  Google Scholar 

  106. Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013;7(3):300–22.

    Article  Google Scholar 

  107. Shuk E, Shoushtari AN, Luke J, Postow MA, Callahan M, Harding JJ, et al. Patient perspectives on ipilimumab across the melanoma treatment trajectory. Support Care Cancer. 2017;25(7):2155–67.

    Article  Google Scholar 

  108. Dieng M, Kasparian NA, Morton RL, Mann GJ, Butow P, Menzies S, et al. The melanoma care study: protocol of a randomised controlled trial of a psycho-educational intervention for melanoma survivors at high risk of developing new primary disease. BMC Psychol. 2015;3(23):1–3.

    Google Scholar 

  109. Koch L, Jansen L, Brenner H, Arndt V. Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors—a systematic review of quantitative studies. Psycho-Oncol. 2013;22(1):1–11.

    Article  Google Scholar 

  110. Bonnaud-Antignac A, Bourdon M, Dreno B, Quereux G. Coping strategies at the time of diagnosis and quality of life 2 years later A study in primary cutaneous melanoma patients. Cancer Nurs. 2017;40(1):E45–53.

    Article  Google Scholar 

  111. Teunissen SCCM, Wesker W, Kruitwagen C, de Haes HCJM, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: A systematic review. J Pain Symptom Manag. 2007;34(1):94–104.

    Article  Google Scholar 

  112. Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer. 2007;110(8):1665–76.

    Article  Google Scholar 

  113. Lloyd-Williams M, Shiels C, Taylor F, Dennis M. Depression – an independent predictor of early death in patients with advanced cancer. J Affect Disord. 2009;113(1–2):127–32.

    Article  Google Scholar 

  114. Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A. A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manag. 2005;29(3):224–37.

    Article  Google Scholar 

  115. Slagelse C, Munch T, Glazer C, Greene K, Finnerup NB, Kashani-Sabet M, et al. Natural history of pain associated with melanoma surgery. Pain Rep. 2018;3(6):e689.

    Article  Google Scholar 

  116. Mamoor M, Postow MA, Lavery JA, Baxi SS, Khan N, Mao JJ, et al. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. J Immunother Cancer. 2020;8(1):e000260.

    Google Scholar 

  117. Beutel ME, Fischbeck S, Binder H, Blettner M, Brahler E, Emrich K, et al. Depression, anxiety and quality of life in long-term survivors of malignant melanoma: a register-based cohort study. Plos One. 2015;10(1):e0116440.

    Google Scholar 

  118. Milne D, Hyatt A, Billett A, Gough K, Krishnasamy M. Exploring the experiences of people treated with immunotherapies for advanced melanoma and those caring for them: “real-world” data. Cancer Nurs. 2020;43(2):E97–E104.

    Article  Google Scholar 

  119. Boyages J, Kalfa S, Xu Y, Koelmeyer L, Mackie H, Viveros H, et al. Worse and worse off: the impact of lymphedema on work and career after breast cancer. Springerplus. 2016;5:657.

    Google Scholar 

  120. Makady A, Kalf RRJ, Ryll B, Spurrier G, de Boer A, Hillege H, et al. Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study. Health Qual Life Outcomes. 2018;16(1):222.

    Article  Google Scholar 

  121. Zucca AC, Boyes AW, Linden W, Girgis A. All’s well that ends well? Quality of life and physical symptom clusters in long-term cancer survivors across cancer types. J Pain Symptom Manag. 2012;43(4):720–31.

    Article  Google Scholar 

  122. Jefford M, Ward AC, Lisy K, Lacey K, Emery JD, Glaser AW, et al. Patient-reported outcomes in cancer survivors: a population-wide cross-sectional study. Support Care Cancer. 2017;25(10):3171–9.

    Article  Google Scholar 

  123. Engel J, Schlesinger-Raab A, Emeny R, Holzel D, Schubert-Fritschle G. Quality of life in women with localised breast cancer or malignant melanoma 2 years after initial treatment: a comparison. Int J Behav Med. 2014;21(3):478–86.

    Article  Google Scholar 

  124. Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol. 2005;23:5814–30.

    Article  Google Scholar 

  125. Freiman A, Yu J, Loutfi A, Wang B. Impact of melanoma diagnosis on sun-awareness and protection: efficacy of education campaigns in a high-risk population. J Cutan Med Surg. 2004;8:303–9.

    Article  Google Scholar 

  126. Oliveria SA, Hay JL, Geller AC, Heneghan MK, McCabe MS, Halpern AC. Melanoma survivorship: research opportunities. J Cancer Surviv. 2007;1(1):87–97.

    Article  Google Scholar 

  127. Grassi L, Spiegel D, Riba M. Advancing psychosocial care in cancer patients. F1000Res. 2017;6:2083.

    Google Scholar 

  128. de la Torre-Luque A, Gambara H, Lopez E, Cruzado JA. Psychological treatments to improve quality of life in cancer contexts: a meta-analysis. Int J Clin Health Psychol. 2016;16(2):211–9.

    Article  Google Scholar 

  129. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Wellington: The Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group; 2008.

    Google Scholar 

  130. McLoone JK, Watts KJ, Menzies SW, Barlow-Stewart K, Mann GJ, Kasparian NA. Melanoma survivors at high risk of developing new primary disease: a qualitative examination of the factors that contribute to patient satisfaction with clinical care. Psychooncology. 2013;22(9):1994–2000.

    Article  Google Scholar 

  131. McLoone J, Menzies S, Meiser B, Mann GJ, Kasparian NA. Psycho-educational interventions for melanoma survivors: a systematic review. Psychooncology. 2013;22(7):1444–56.

    Article  Google Scholar 

  132. Beatty L, Kemp E, Binnion C, Turner J, Milne D, Butow P, et al. Uptake and adherence to an online intervention for cancer-related distress: older age is not a barrier to adherence but may be a barrier to uptake. Support Care Cancer. 2017;25(6):1905–14.

    Article  Google Scholar 

  133. Butow P, Turner J, Gilchrist J, Sharpe L, Smith AB, Fardell JE, et al. Randomized trial of conquer fear: a novel, theoretically based psychosoical intervention for fear of cacner recurrence. J Clin Oncol. 2017;35(36):4066–77.

    Article  Google Scholar 

  134. Beatty L, Kemp E, Wade T, Koczwara B, Finding my way study I. Finding my way: protocol of a randomised controlled trial evaluating an internet self-help program for cancer-related distress. BMC Cancer. 2015;15:328.

    Google Scholar 

  135. Berg CJ, Vanderpool RC, Getachew B, Payne JB, Johnson MF, Sandridge Y, et al. A hope-based intervention to address disrupted goal pursuits and quality of life among young adult cancer survivors. J Cancer Educ. 2020;35(6):1158–69.

    Google Scholar 

  136. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Distress management. Version1. Fort Washington: National Comprehensive Cancer Network; 2020.

    Google Scholar 

  137. Bares CB, Trask PCS, Schwartz SM. An exercise in cost-effectiveness analysis: treating emotional distress in melanoma patients. J Clin Psychol Med Settings. 2002;9(3):193–200.

    Article  Google Scholar 

  138. Trask PC, Paterson AG, Griffith KA, Riba MB, Schwartz JL. Cognitive-behavioral intervention for distress in patients with melanoma: comparison with standard medical care and impact on quality of life. Cancer. 2003;98(4):854–64.

    Article  Google Scholar 

  139. Russell L, Ugalde A, Orellana L, Milne D, Krishnasamy M, Chambers R, et al. A pilot randomised controlled trial of an online mindfulness-based program for people diagnosed with melanoma. Support Care Cancer. 2019;27(7):2735–46.

    Article  Google Scholar 

  140. Dieng M, Morton RL, Costa DSJ, Butow PN, Menzies SW, Lo S, et al. Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomized controlled trial. Br J Dermatol. 2020;182(4):860–8.

    Article  Google Scholar 

  141. Dieng M, Kasparian NA, Morton RL, Mann GJ, Butow P, Menzies S, et al. The melanoma care study: protocol of a randomised controlled trial of a psycho-educational intervention for melanoma survivors at high risk of developing new primary disease. BMC Psychol. 2015;3(1):23.

    Article  Google Scholar 

  142. Kasparian NA, Mireskandari S, Butow PN, Dieng M, Cust AE, Meiser B, et al. “Melanoma: questions and answers.” Development and evaluation of a psycho-educational resource for people with a history of melanoma. Support Care Cancer. 2016;24(12):4849–59.

    Article  Google Scholar 

  143. Dieng M, Kasparian NA, Mireskandari S, Butow P, Costa D, Morton R, et al. Psychoeducational intervention for people at high risk of developing another melanoma: a pilot randomised controlled trial. BMJ Open. 2017;7(10):e015195.

    Google Scholar 

  144. Dieng M, Khanna N, Kasparian NA, Costa DSJ, Butow PN, Menzies SW, et al. Cost-effectiveness of a psycho-educational intervention targeting fear of cancer recurrence in people treated for early-stage melanoma. Appl Health Econ Health Policy. 2019;17(5):669–81.

    Article  Google Scholar 

  145. Fawzy FI, Cousins N, Fawzy NWK, Kemeny ME, Elashoff R, Morton D. A structured psychiatric intervention for cancer patients I. Changes over time in methods of coping and affective disturbance. Arch Gen Psychiatry. 1990;47:720–5.

    Google Scholar 

  146. Fawzy FI, Kemeny ME, Fawzy NW, Elashoff R, Morton D, Cousins N, et al. A structured psychiatric intervention for cancer patients II. Changes over time in immunological measures. Arch Gen Psychiatry. 1990;47:729–35.

    Google Scholar 

  147. Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, et al. Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry. 1993;50(9):681–9.

    Article  Google Scholar 

  148. Fawzy FI, Canada AL, Fawzy NW. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch Gen Psychiatry. 2003;60(1):100–3.

    Article  Google Scholar 

  149. Boesen EH, Ross L, Frederiksen K, Thomsen BL, Dahlstrom K, Schmidt G, et al. Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol. 2005;23(6):1270–7.

    Article  Google Scholar 

  150. Boesen EH, Boesen SH, Frederiksen K, Ross L, Dahlstrom K, Schmidt G, et al. Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol. 2007;25(36):5698–703.

    Article  Google Scholar 

  151. Fawzy NW. A psychoeducational nursing intervention to enhance coping and affective state in newly diagnosed malignant melanoma patients Cancer Nurs. 1995;18(6):427–38.

    Google Scholar 

  152. Pedersen AF, Schmidt H, Trautner T, Jensen AB. Participation in an unstructured supportive group as experienced by patients with advanced cancer disease: a preliminary study. Acta Oncol. 2009;48(7):1074–7.

    Article  Google Scholar 

  153. Berezowska A, Passchier E, Bleiker E. Professional patient navigation in a hospital setting: a randomized controlled trial. Support Care Cancer. 2021;29(4):2111–23.

    Google Scholar 

  154. Berezowska A, Passchier E, Bleiker E. Evaluating a professional patient navigation intervention in a supportive care setting. Support Care Cancer. 2019;27(9):3281–90.

    Article  Google Scholar 

  155. Kotronoulas G, Connaghan J, Grenfell J, Gupta G, Smith L, Simpson M, et al. Employing patient-reported outcome (PRO) measures to support newly diagnosed patients with melanoma: feasibility and acceptability of a holistic needs assessment intervention. Eur J Oncol Nurs. 2017;31:59–68.

    Google Scholar 

  156. Fox J, Janda M, Bennett F, Langbecker D. An outreach telephone program for advanced melanoma supportive care: acceptability and feasibility. Eur J Oncol Nurs. 2019;42:110–5.

    Google Scholar 

  157. Lacey J, Lomax AJ, McNeil C, Marthick M, Levy D, Kao S, et al. A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability. Support Care Cancer. 2019;27(4):1497–507.

    Article  Google Scholar 

  158. Lynch FA, Katona L, Jefford M, Smith AB, Shaw J, Dhillon HM, et al. Feasibility and acceptability of fear-less: a stepped-care program to manage fear of cancer recurrence in people with metastatic melanoma. J Clin Med. 2020;9(9):2969.

    Google Scholar 

  159. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009;7:102.

    Article  Google Scholar 

  160. Quinten C, Martinelli F, Coens C, Sprangers MA, Ringash J, Gotay C, et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 2014;120(2):302–11.

    Article  Google Scholar 

  161. Boyle DA. Psychological adjustment to the melanoma experience. Semin Oncol Nurs. 2003;19(1):70–7.

    Article  Google Scholar 

  162. Gogas HJ, Karalexi MA, Dessypris N, Antoniadis AG, Papadopoulos F, Petridou ET. The role of depression and personality traits in patients with melanoma: a South-European study. Melanoma Res. 2017;27(6):625–31.

    Article  Google Scholar 

  163. Brown JE, Butow PN, Culjak G, Coates AS, Dunn SM. Psychosocial predictors of outcome: time to relapse and survival in patients with early stage melanoma. Br J Cancer. 2000;83(11):1448–53.

    Article  Google Scholar 

  164. Coates A, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer. 1993;29A(12):1731–4.

    Article  Google Scholar 

  165. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol. 1999;17(7):2256–63.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia

    Robyn P. M. Saw, Iris Bartula, Rachael L. Morton, Mbathio Dieng, Julia Lai-Kwon, Jake Thompson & Niyaz Mostafa

  2. Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia

    Robyn P. M. Saw

  3. Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

    Robyn P. M. Saw & Iris Bartula

  4. Patricia Ritchie Centre for Research and Cancer Care, Northern Clinical School, The University of Sydney, Sydney, NSW, Australia

    Julie B. Winstanley

  5. White Winstanley Ltd, Lymm, Cheshire, UK

    Julie B. Winstanley

  6. NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia

    Rachael L. Morton & Mbathio Dieng

  7. Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia

    Niyaz Mostafa

Authors
  1. Robyn P. M. Saw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iris Bartula
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julie B. Winstanley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rachael L. Morton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mbathio Dieng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Julia Lai-Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jake Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Niyaz Mostafa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robyn P. M. Saw .

Editor information

Editors and Affiliations

  1. Department of Applied Health Research, University College London, London, UK

    Angelos P. Kassianos

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Saw, R.P.M. et al. (2022). Melanoma and Quality of Life. In: Kassianos, A.P. (eds) Handbook of Quality of Life in Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-84702-9_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-84702-9_26

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-84701-2

  • Online ISBN: 978-3-030-84702-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation